US Indymedia Global Indymedia Publish About us
Printed from Boston IMC : http://boston.indymedia.org/
Boston.Indymedia
IVAW Winter Soldier

Winter Soldier
Testimonies
Brad Presente

Other Local News

Spare Change News
Open Media Boston
Somerville Voices
Cradle of Liberty
The Sword and Shield

Local Radio Shows

WMBR 88.1 FM
What's Left
WEDS at 8:00 pm
Local Edition
FRI (alt) at 5:30 pm

WMFO 91.5 FM
Socialist Alternative
SUN 11:00 am

WZBC 90.3 FM
Sounds of Dissent
SAT at 11:00 am
Truth and Justice Radio
SUN at 6:00 am

Create account Log in
Comment on this article | View comments | Email this article | Printer-friendly version
News ::
Why Interferon's Do Not Work and Boosting the Immune System Does (english)
28 Apr 2003
Modified: 06:44:48 AM
Scientists at two Texas universities have discovered how hepatitis C virus thwarts immune system efforts to eliminate it.





 



Why Interferon's Do Not Work
and Boosting the Immune System Does








Scientists at two Texas universities have discovered how

hepatitis C virus thwarts immune system efforts to eliminate it.  The finding, published
online today in "ScienceExpress",
could lead to more effective treatments for liver disease
caused by hepatitis C virus, says author Michael Gale,
Jr., Ph.D., of University of Texas Southwestern Medical
Center at Dallas. Dr. Gale and coauthor Stanley Lemon,
M.D., of University of Texas Medical Branch at Galveston,
are grantees of the National Institute of Allergy and Infectious Diseases

(NIAID).

"Persistent hepatitis C virus (HCV) infection is
a major cause of liver
disease worldwide and is the leading reason for liver
transplants in this
country," notes NIAID Director Anthony S. Fauci,
M.D. "The most prevalent form of HCV in the United States is,

unfortunately, the
least responsive
to available treatments. Moreover, African Americans are
even less responsive to therapy than Caucasians,"
he adds.

The immune system has many ways to detect and fight off
invading microbes, and microbes have just as many ways
to elude and disarm immune system components. Through
a series of experiments on cells grown in the laboratory,
Drs. Gale and Lemon defined the strategy HCV uses to evade
the host's immune response. As HCV begins to replicate
in its human host, it manufactures enzymes, called proteases,
which it requires to transform viral proteins into their
functional forms. The Texas investigators determined that
one viral protease, NS3/4A, specifically inhibits a key
immune system molecule, interferon regulatory factor-3
(IRF-3). IRF-3 orchestrates a range of antiviral responses.
Without this master switch, antiviral responses never
begin, and HCV can gain a foothold and persist in its
host.

Next, the scientists searched for ways to reverse the
IRF-3 blockade.  They applied a protease inhibitor
to human cells containing modified HCV. This prevented
the virus from making functional NS3/4A and restored the
cells' IRF-3 pathway. Follow-up studies have shown that
once restored, the immune response reduced viral levels
to nearly undetectable levels within days, according to
Dr. Gale.

The identification of this viral protease-regulated control
of IRF-3 opens
new avenues in both clinical and basic research on hepatitis
C, notes Dr.
Gale. Until now, scientists had not considered the possibility
that inhibiting this protease did anything more than halt
viral replication. "Now that we know NS3/4A inhibition
essentially restores the host's immune response to the
virus, we can assess hepatitis drug candidates for this
ability as well," Dr. Gale says.

NS3/4A will be a valuable tool in further dissecting the
roles of viral proteases and their host cell targets,
says Dr. Gale. For example, the
scientists plan to use NS3/4A to hunt for the still unknown
host cell enzyme responsible for activating IRF-3. Conceivably,
Dr. Gale explains, future therapeutic approaches to viral
disease could involve boosting the
activity of any key host enzymes that are found.

"Understanding the tricks that the hepatitis C virus
employs to impair the
immune system represents an important advance with potential
implications for successful cure of those suffering from liver

disease,"
says Leslye
Johnson, Ph.D., chief of NIAID's enteric and hepatic diseases
branch.

NIAID is a component of the National Institutes of Health
(NIH), which is
an agency of the Department of Health and Human Services.
NIAID supports basic and applied research to prevent,
diagnose, and treat infectious and immune-mediated illnesses,
including HIV/AIDS and other sexually transmitted diseases,
illness from potential agents of bioterrorism, tuberculosis,
malaria, autoimmune disorders, asthma and allergies.

National Institutes of Health
 




See also:
http://www.HepCSolutions.com
Add a quick comment
Title
Your name Your email

Comment

Text Format
Anti-spam Enter the following number into the box:
To add more detailed comments, or to upload files, see the full comment form.

Comments

relevance? (english)
28 Apr 2003
I ain't gonna read this article. What's it doing here?